Explanted Lung Tissues With Pulmonary Fibrosis

Status Recruiting

Clinical Trial Summary

The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.

Clinical Trial Description

Pulmonary Fibrosis involves scarring of the lung. Gradually, the air sacs of the lungs become replaced by fibrotic tissue. The most current thinking is that the fibrotic process is a reaction to tiny injury to the lung. When the scar forms, the tissue becomes thicker causing a permanent loss of the tissue's ability to carry oxygen into the bloodstream. We need to obtain lung tissue from patients without pulmonary fibrosis and compare it to lung tissue from patients with pulmonary fibrosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00515567
Study type	Observational
Source	University of Chicago
Contact	Nickolai Dulin, MD
Email	ndulin@bsd.uchicago.edu
Status	Recruiting
Phase
Start date	February 2006
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04638517` - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis	Phase 2
Recruiting	`NCT05299333` - Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis	N/A
Terminated	`NCT04119115` - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01417156` - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)	Phase 2
Terminated	`NCT00981747` - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis	Phase 2/Phase 3
Completed	`NCT00001596` - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome	Phase 2
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT01442779` - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis	Phase 2
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Recruiting	`NCT00001532` - Role of Genetic Factors in the Development of Lung Disease
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Recruiting	`NCT04864990` - Dyspnea and Idiopathic Pulmonary Fibrosis
Completed	`NCT01961362` - Supplemental Oxygen in Pulmonary Fibrosis
Completed	`NCT01271842` - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study	N/A
Completed	`NCT00650091` - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF	Phase 3
Active, not recruiting	`NCT00258544` - Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Enrolling by invitation	`NCT04930289` - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Enrolling by invitation	`NCT06327360` - Illness Expectations in Pulmonary Fibrosis